سعر اندليكسابان 5مجم 20 قرص 2023

Endlixaban (apixaban) 5 mg film-coated tablets (red to brick-red round biconvex), box of 20 tablets (2 blisters x 10), ATCO Pharma, Egypt. Oral direct factor Xa inhibitor anticoagulant.

• Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors (prior stroke/TIA, age >=75 years, hypertension, diabetes, symptomatic heart failure NYHA >=II).Population: AdultsATCO Pharma (manufacturer, Egypt)
• Treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent DVT and PE in adults.Population: AdultsATCO Pharma (manufacturer, Egypt)

• Common: anaemia, haemorrhage/haematoma, eye haemorrhage, epistaxis, nausea, gastrointestinal, rectal and gingival bleeding, hypotension; thrombocytopenia (common in VTE treatment). Uncommon/rare: brain haemorrhage, hypersensitivity, abnormal liver tests.Egyptian label · ATCO Pharma (manufacturer, Egypt)

• Hypersensitivity to apixaban or excipients; active clinically significant bleeding; hepatic disease with coagulopathy and clinically relevant bleeding risk.Egyptian label · ATCO Pharma (manufacturer, Egypt)
• Lesions or conditions at significant risk of major bleeding (e.g. recent GI ulceration, high-risk malignancy, recent brain/spinal injury or surgery, recent intracranial haemorrhage, oesophageal varices, vascular malformations).Egyptian label · ATCO Pharma (manufacturer, Egypt)
• Concomitant treatment with any other anticoagulant (UFH, LMWH, fondaparinux, warfarin, rivaroxaban, dabigatran, etc.) except when switching therapy or UFH at catheter-maintenance doses or during AF catheter ablation.Egyptian label · ATCO Pharma (manufacturer, Egypt)

• Haemorrhage risk: observe for bleeding; caution with antiplatelets, SSRIs/SNRIs and NSAIDs; discontinue if severe haemorrhage occurs.Egyptian label · ATCO Pharma (manufacturer, Egypt)
• Not recommended in patients with prosthetic heart valves, or with antiphospholipid syndrome (especially triple-positive); not a substitute for heparin in haemodynamically unstable PE or patients needing thrombolysis/embolectomy.Egyptian label · ATCO Pharma (manufacturer, Egypt)
• Stop at least 48 h before elective surgery with moderate/high bleeding risk and at least 24 h before low-risk procedures; premature discontinuation increases thrombotic risk - restart as soon as possible.Egyptian label · ATCO Pharma (manufacturer, Egypt)

• Strong inhibitors of both CYP3A4 and P-gp (ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir)Not recommended: may increase apixaban exposure about 2-fold.ATCO Pharma (manufacturer, Egypt)
• Strong inducers of both CYP3A4 and P-gp (rifampicin, phenytoin, carbamazepine, phenobarbital, St John's wort)About 50% reduction in apixaban exposure; use with caution for NVAF/recurrence prevention and do not use for DVT/PE treatment.ATCO Pharma (manufacturer, Egypt)
• Other anticoagulants; antiplatelet agents, SSRIs/SNRIs, NSAIDsOther anticoagulants contraindicated; antiplatelets, SSRIs/SNRIs and NSAIDs increase bleeding risk.ATCO Pharma (manufacturer, Egypt)

• No data on use in pregnant women; apixaban is not recommended during pregnancy.Egyptian label · ATCO Pharma (manufacturer, Egypt)
• US label: limited data insufficient to inform drug-associated risks; treatment may increase bleeding risk during pregnancy and delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether apixaban is excreted in human milk; a risk to infants cannot be excluded - discontinue breastfeeding or apixaban.Egyptian label · ATCO Pharma (manufacturer, Egypt)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and prothrombinase activity, decreasing thrombin generation; no direct effect on platelet aggregation (US label).

Store at temperature not exceeding 30 °C in a dry place.